Tango Therapeutics
Tracked across 1 events · 8 articles · First seen Jun 08, 2026 · Last active Jun 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Tango Therapeutics, a clinical-stage biotechnology company, announced and subsequently priced an upsized underwritten public offering of its common stock and pre-funded warrants. Initially proposed at $500 million, the offering was priced to generate approximately $600…
Impact: Tango Therapeutics launched and priced an upsized public offering of its common stock and pre-funded warrants, expecting to raise approximately $600 million in gross proceeds. This offering will provide capital for its operations and drug development.
Jun 08, 2026 · 8 articles
100
Tango Therapeutics announced proposed offeringTango Therapeutics Upsized...
70
Tango Therapeutics granted option to underwritersTango Therapeutics Upsized...
70
JPMorgan Chase acted as manager Tango TherapeuticsTango Therapeutics Upsized...
70
Leerink Partners acted as manager Tango TherapeuticsTango Therapeutics Upsized...
70
Cantor Fitzgerald acted as manager Tango TherapeuticsTango Therapeutics Upsized...
70
Stifel acted as manager Tango TherapeuticsTango Therapeutics Upsized...
NEWSDESK
Track Tango Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard